Welcome to our dedicated page for TAKEDA PHARMACEUTICAL CO SEC filings (Ticker: TKPHF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on TAKEDA PHARMACEUTICAL CO's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into TAKEDA PHARMACEUTICAL CO's regulatory disclosures and financial reporting.
Takeda Pharmaceutical Company Limited reports that a U.S. federal jury in Massachusetts returned a verdict against the company in AMITIZA (lubiprostone) antitrust litigation, awarding plaintiffs USD 884,943,990 in single damages. This includes USD 474,897,965 for a wholesaler class and USD 346,837,646 for individual retailers, which are subject to automatic trebling under U.S. antitrust law upon entry of judgment. Damages for an end payor class remain subject to further court proceedings.
Takeda states it will vigorously pursue post-trial motions and an appeal and notes the verdict is not enforceable until judgment is entered. The company is assessing a provision to recognize in its consolidated financial statements for the fiscal year ended March 31, 2026 and plans to revise and re-file its FY2025 earnings and related materials once the amount is determined. Takeda indicates this outcome will not affect FY2025 Core financial results and does not expect a material impact on its FY2026 financial forecast or Management Guidance, other than potential changes to adjusted free cash flow depending on the amount and timing of any payment.
Takeda Pharmaceutical Co. Ltd. filed an initial Form 3 for executive Jennifer Marie Smoter, who serves as Chief Communications & Government Officer. The filing does not report any insider transactions or holdings; it simply establishes her status as a reporting person for future disclosures.
Takeda Pharmaceutical’s President and CEO Christophe Weber received new equity-based compensation awards. On April 27, 2026 he was granted 165,370 American Depositary Shares and 78,900 Ordinary Shares at no cash cost, described as grant or award acquisitions.
The filing notes these awards stem from restricted stock units granted on July 1, 2023, whose final amounts were set by the Compensation Committee based on performance metrics including core revenue, core operating profit and important R&D milestones. Following these grants, Weber directly holds 418,803 American Depositary Shares and 1,014,200 Ordinary Shares.
He also received 78,978 Tax Obligation Awards, each economically equivalent to one Ordinary Share and settling in cash primarily to cover tax obligations at the then-current Ordinary Share market price. After this grant, he holds 125,345 Tax Obligation Awards, alongside additional RSU positions scheduled to vest between 2026 and 2028.
Furuta Milano reported acquisition or exercise transactions in this Form 4 filing.
Takeda Pharmaceutical director and Chief Financial Officer Furuta Milano received equity-based compensation rather than buying shares on the market. On April 27, 2026, Milano was awarded 7,800 Ordinary Shares at no cost following performance-based RSUs tied to core revenue, core operating profit, and R&D milestones, bringing direct ownership to 57,900 Ordinary Shares.
The filing notes that this total includes 27,300 restricted stock units (RSUs), which are scheduled to vest as Ordinary Shares on June 1, 2026 (16,200 shares), June 1, 2027 (7,100 shares) and June 1, 2028 (4,000 shares). Milano also received 7,814 Tax Obligation Awards, economically equivalent to Ordinary Shares but payable in cash at vest primarily to cover tax obligations, with 16,619 such derivative awards held afterward.
Plump Andrew Stewart reported acquisition or exercise transactions in this Form 4 filing.
Takeda Pharmaceutical Co. Ltd. director and President of R&D Andrew Stewart Plump reported a compensation-related equity award. On April 27, 2026, he was credited with 212,470 American Depositary Shares at $0.00 per share as a grant/award linked to earlier restricted stock units.
The award stems from RSUs originally granted on July 1, 2023, which vest in ADSs based on performance metrics including core revenue, core operating profit, and key R&D milestones. After the award, he directly holds 806,572 ADS and indirectly holds 281,307 ADS through a trust. The filing notes unvested RSUs scheduled to vest on July 1, 2026 (329,478 shares), July 1, 2027 (91,580 shares), and July 1, 2028 (43,374 shares), each representing a contingent right to receive one ADS.
Ricci Gabriele reported acquisition or exercise transactions in this Form 4 filing.
Takeda Pharmaceutical granted Chief Data & Technology Officer Gabriele Ricci 34,994 American Depositary Shares on April 27, 2026 as a compensation-related award. This follows a July 1, 2023 grant of restricted stock units tied to performance metrics such as core revenue, core operating profit and important R&D milestones.
After this award, Ricci holds 159,126 American Depositary Shares, including 80,768 restricted stock units. These RSUs are scheduled to vest in tranches on July 1, 2026, July 1, 2027 and July 1, 2028, reflecting a multi‑year incentive structure rather than an open‑market transaction.
Takeda Pharmaceutical reported that President, OBU Teresa Marie Bitetti acquired 64,988 American Depositary Shares at no cost through a performance-based equity award. These shares reflect restricted stock units granted on July 1, 2023, with the final amount determined on April 27, 2026 based on core revenue, core operating profit, and R&D milestones.
Following this award, Bitetti holds 258,136 American Depositary Shares, including 150,790 restricted stock units that will vest in stages on July 1, 2026, July 1, 2027, and July 1, 2028, tying a substantial portion of her compensation to Takeda’s future performance.
Takeda Pharmaceutical Co Ltd Chief Transformation Officer Lauren Rusckowski Duprey received an equity award tied to performance goals. On April 27, 2026, she was granted 59,990 American Depositary Shares at a price of $0.00 per share as a grant or award acquisition.
After this award, she directly holds 228,503 American Depositary Shares, including 146,762 restricted stock units that may convert into shares. These RSUs vest on a schedule: 100,658 shares on July 1, 2026, 30,488 shares on July 1, 2027, and 15,616 shares on July 1, 2028, contingent on prior performance metrics such as core revenue, core operating profit, and important R&D milestones.
Kim Julie So-Young reported acquisition or exercise transactions in this Form 4 filing.
Takeda Pharmaceutical reported that CEO-elect Julie So-Young Kim received a grant of 105,416 American Depositary Shares (ADS) on April 27, 2026, following performance-based RSU metrics set from a July 1, 2023 award. After this grant, she holds 430,145 ADS, including 256,372 RSUs that vest in stages from July 1, 2026 through July 1, 2028.
Platford Giles Richard reported acquisition or exercise transactions in this Form 4 filing.
Takeda Pharmaceutical executive Giles Richard Platford, President IBU, received a grant of 72,124 American Depositary Shares on April 27, 2026 as a performance-based restricted stock unit (RSU) award at no cash cost to him.
The award was determined by the Compensation Committee using performance metrics including core revenue, core operating profit and important R&D milestones from an RSU grant originally made on July 1, 2023. Following this award, Platford directly holds 297,363 American Depositary Shares, including 166,744 RSUs scheduled to vest on July 1, 2026 (116,762 shares), July 1, 2027 (32,396 shares) and July 1, 2028 (17,586 shares).